{
    "2021-01-26": [
        [
            {
                "time": "2021-02-04",
                "original_text": "Coronavirus update: J&J to release vaccine data next week; strain from Brazil confirmed in US",
                "features": {
                    "keywords": [
                        "J&J",
                        "vaccine",
                        "Brazil",
                        "strain",
                        "US"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2021-02-09",
                "original_text": "New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percent",
                "features": {
                    "keywords": [
                        "etesevimab",
                        "bamlanivimab",
                        "COVID-19",
                        "hospitalizations",
                        "death",
                        "reduced"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-02-10",
                "original_text": "Eli Lilly and Regeneron Report More Positive Data on Covid-19 Antibody Cocktails",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Regeneron",
                        "Covid-19",
                        "Antibody",
                        "Cocktails",
                        "Positive Data"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-02-11",
                "original_text": "Regeneron's (REGN) Performance Strong in 2020: What Lies Ahead?",
                "features": {
                    "keywords": [
                        "Regeneron",
                        "Performance",
                        "Strong",
                        "2020",
                        "Ahead"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-02-12",
                "original_text": "Lilly says late-stage study showed combo therapy can reduce deaths and hospitalizations in COVID-19 patients",
                "features": {
                    "keywords": [
                        "Lilly",
                        "late-stage",
                        "study",
                        "combo",
                        "therapy",
                        "reduce",
                        "deaths",
                        "hospitalizations",
                        "COVID-19"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-02-13",
                "original_text": "General Electric, Johnson & Johnson - Tuesday's Premarket Movers",
                "features": {
                    "keywords": [
                        "General Electric",
                        "Johnson & Johnson",
                        "Premarket Movers"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "industrial",
                        "healthcare"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-02-14",
                "original_text": "The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market",
                "features": {
                    "keywords": [
                        "Novartis",
                        "J&J",
                        "Big Pharma",
                        "Earnings",
                        "Vaccine",
                        "CureVac",
                        "Equity Market"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-02-15",
                "original_text": "Eli Lilly Shares Gain After Positive Data From Late-Stage Covid Treatment Trial",
                "features": {
                    "keywords": [
                        "Eli Lilly",
                        "Shares",
                        "Gain",
                        "Positive Data",
                        "Late-Stage",
                        "Covid",
                        "Treatment",
                        "Trial"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-02-16",
                "original_text": "New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent",
                "features": {
                    "keywords": [
                        "Lilly",
                        "neutralizing",
                        "antibodies",
                        "bamlanivimab",
                        "etesevimab",
                        "COVID-19",
                        "hospitalizations",
                        "death",
                        "reduced"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}